What Happens After the PCAC Vote
A recommendation is the first of four stages, and the other three have no deadline. What has to happen before a pharmacy may compound any of these peptides.
The most common question since the July 2026 vote is a reasonable one: when can a pharmacy actually make this?
The honest answer is that nobody knows, and the reason nobody knows is more useful than a guess would be. A committee recommendation is the first of four stages, and the three that follow have no deadline attached to any of them.
The four stages
| Stage | What it is | Status for the six recommended peptides |
|---|---|---|
| 1. Committee recommendation | PCAC evaluates and advises | Done — July 2026 |
| 2. FDA decision | Agency accepts, modifies or rejects | Not started |
| 3. Notice-and-comment rulemaking | Proposed rule, comment period, response | Not started |
| 4. Final rule | Substance actually added to the list | Not started |
Everything reported in July was stage one. The distance between stage one and stage four is where every confident timeline falls apart.
Why the committee cannot decide this
The Pharmacy Compounding Advisory Committee is advisory. That word is the whole of its function, not a caveat on it.
Its role is to evaluate a nominated substance against the statutory criteria and to tell the agency what it concluded. FDA is free to accept that conclusion, modify it, or reject it. Beyond the agency, addition to the 503A Bulks List requires formal approval by the Secretary of Health and Human Services.
So a vote is a well-informed opinion recorded on a particular day by people appointed to give one. It is genuine evidence about how the expert case looks. It is not a decision, and it does not alter what any pharmacy may lawfully do the following morning.
What rulemaking involves
Stage three is the long one, and it is long by design rather than by neglect.
Adding a substance to the list is a change to a federal regulation, which means notice-and-comment rulemaking: FDA publishes a proposed rule, opens a public comment period — typically in the range of 60 to 90 days — then reviews and responds to the comments received, and finally publishes a final rule.
The comment stage is not a formality. Anyone may file, and the agency has to engage with what comes in. Manufacturers of competing approved products, professional bodies, compounding pharmacies and members of the public all have standing to make the case in either direction, and on a set of substances this commercially contested the volume is unlikely to be small.
There is no statutory deadline on any of stages two through four. Legal commentary after the July vote converged on roughly eight to twenty-four months as realistic, reasoning from how earlier 503A additions have moved. That is an inference drawn from precedent, not a timetable FDA has committed to, and it should be read as an order of magnitude rather than a forecast.
The category question, which is separate
Running underneath all of this is a different classification that gets confused with the list itself.
While nominated substances await evaluation, FDA sorts them under an interim policy. Category 1 covers substances the agency has identified as potentially eligible, and it carries an interim enforcement policy under which FDA does not generally act against compounding. Category 2 covers substances raising significant safety risks, and that policy does not extend to them.
Two consequences are routinely misreported.
Removal from Category 2 is not promotion to Category 1. When FDA announced on 15 April 2026 that it would remove twelve peptides from Category 2, the stated reason was that the nominations had been withdrawn by the nominators. That is procedural housekeeping. A substance can leave Category 2 and authorise nothing at all, because being outside the risk category is not the same as being inside the permissive one.
And the categories are an interim arrangement pending evaluation. The Bulks List is the durable outcome. They are different instruments answering different questions.
Where each compound stands
The six recommended in July — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax — are all at stage one, with stage two not yet begun. Their recommendations carried different margins, but the margin does not affect the procedural position: a narrow yes and a wide yes enter stage two identically.
Emideltide received no recommendation and has no route forward from this cycle. It remains in Category 2.
Thymosin alpha-1 is worth noting because it is frequently swept into coverage of this vote and was not part of it. It went before the committee in December 2024, FDA’s position was that it should not be included, and the committee voted against adding it. It was not on the July 2026 agenda.
What none of this touches
Three things sit entirely outside this process, and conflating them with it produces most of the confusion in circulation.
Approval as a medicine. Nothing here approves anything. A compoundable substance is one a pharmacy may prepare against a prescription; it has not been through the evidence review that produces a marketing authorisation. The distinction between approved and compoundable is the one most worth holding onto.
Research-chemical sales. A substance on the Bulks List may be compounded by a licensed pharmacy for a patient with a prescription. That is not the same channel as a vial sold online for research use, and a listing would not make that channel lawful.
Anything in Europe. The 503A mechanism is US federal law with no EU equivalent. A peptide added to the list becomes compoundable by an American pharmacy and nothing more. For a reader in the EU, this entire process changes nothing.
How to read the next twelve months
There will be more coverage, and it will arrive in stages that look like news and mostly are not.
A proposed rule is genuinely newsworthy — it means stage two concluded favourably and stage three has begun. A comment period closing is not. Individual submissions during the comment period are not, however loudly they are announced. A final rule is the one that matters, and it is the only event after which a pharmacy may actually compound.
The reliable tell is whether a piece of writing distinguishes a recommendation from a rule. Anything that does not is either confused or selling something, and after July 2026 a great deal of it has been the latter.
Frequently asked questions
When will BPC-157 be legal to compound?
Nobody can answer this with a date, and anyone offering one is guessing. A favourable committee recommendation is the first step of four. FDA must decide whether to accept it, then conduct notice-and-comment rulemaking — a proposed rule, a public comment period, a response to those comments, and a final rule. There is no statutory deadline on any of it. Legal commentary following the July 2026 vote put the realistic range at roughly eight to twenty-four months based on how earlier additions have moved, but that is an inference from precedent rather than a schedule FDA has published.
Does a PCAC recommendation bind the FDA?
No. The Pharmacy Compounding Advisory Committee is advisory, which is not a technicality but the defining feature of what it does. Its role is to evaluate substances against the statutory criteria and advise the agency. FDA retains full discretion to accept the recommendation, modify it, or reject it outright. Addition to the 503A Bulks List also requires formal approval by the Secretary of Health and Human Services. A committee vote is therefore evidence of where expert opinion landed on one day, not a change in what any pharmacy may lawfully do.
What is the difference between Category 1 and Category 2?
They are groupings under FDA's interim policy while nominated substances await evaluation, and they carry opposite practical consequences. Category 1 substances are those FDA has identified as potentially eligible, and they fall under an interim enforcement policy under which the agency does not generally take action against compounding. Category 2 substances raise significant safety risks, and compounding with them is not covered by that policy. Removal from Category 2 is not the same as promotion to Category 1, and does not on its own authorise anything.
Does any of this apply outside the United States?
No. The 503A framework is a provision of United States federal law governing what a state-licensed compounding pharmacy may prepare for an individual patient. It has no equivalent in European Union medicines law, which does not contain a comparable bulk-substance mechanism. A peptide added to the 503A Bulks List would become compoundable by a US pharmacy against a prescription — it would not become authorised as a medicine anywhere, and it would not change the position of an unapproved product sold in Europe.